Work

Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours

Year: 2021

Type: article

Study design: Clinical Trial

Source: British Journal of Cancer

DOI: 10.1038/s41416-021-01389-8

Authors: Jordi Rodon, Guillem Argilés, Roisin M. Connolly, Ulka Vaishampayan, Maja de Jonge, Elena Garralda, Marios Giannakis, David C. Smith, Jason R. Dobson, Margaret E. McLaughlin, Abdelkader Seroutou, Yan Ji, Jennifer Morawiak, Susan E. Moody, Filip Janku

Institutions: Universitat Autònoma de Barcelona, The University of Texas MD Anderson Cancer Center, Vall d'Hebron Hospital Universitari, University College Cork, Johns Hopkins Medicine, Sidney Kimmel Comprehensive Cancer Center, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Erasmus MC, Erasmus MC Cancer Institute, Harvard University, Dana-Farber Cancer Institute, University of Michigan, Novartis (Switzerland)

Language: English

Topic: Wnt/β-catenin signaling in development and cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Novartis Pharmaceuticals Corporation, National Institutes of Health, National Center for Advancing Translational Sciences

Award: Center for Clinical and Translational Sciences (CCTS)

OpenAlex ID: W3159588552

FWCI: 6.797

Cites: 31

Cited by: 188

Related to: 10